The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope
about
Effects of dendritic cells transfected with full-length wild-type p53 and stimulated by gastric cancer lysates on immune responsePeptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens.CD8+ T cell recognition of polymorphic wild-type sequence p53(65-73) peptides in squamous cell carcinoma of the head and neck.Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells.T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck.Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed?Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomasMelanoma cancer vaccines and anti-tumor T cell responses.TAA polyepitope DNA-based vaccines: a potential tool for cancer therapyXenogene vaccination in the therapy of cancer.Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue.Modulation of the strength and character of HIV-specific CD8+ T cell responses with heteroclitic peptides.Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.Generation and immunosuppressive functions of p53-induced human adaptive regulatory T cells.Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
P2860
Q28388824-192DBE20-2991-4A7B-B6C5-D62A49153988Q33529578-94B2106F-51CF-4A6D-B234-02F1B86BDE09Q33942390-EEC5F490-C00A-497C-B3BA-5190B7B0FB26Q34155839-544FE769-E421-4FE3-8808-B682656956A8Q34475726-34D14969-275B-4A10-B142-81CD4E11AE97Q35142669-1CD28637-2FA1-4C18-BB97-7B909F5DC8BFQ35677112-0A689870-65E3-4DB3-AFB8-455F96F6C108Q35750299-70B952C7-26BB-494A-8A1C-8293F0465D7AQ36019207-2ECA86F5-316B-4F29-8987-C2D1C681D06AQ36129743-697253D1-F0B8-4988-9F60-541E13709857Q36890187-673EBEB2-343B-4FEE-B0DD-F19327861292Q37771268-D688A589-7D3A-4EB7-B1C4-828B81316D3EQ38229368-0BE3654E-C890-44F9-80C7-64362DBC40FFQ39886839-15CD40FF-B63C-482E-BBCE-1958824FD103Q40047262-47A0E29A-ADC3-4C2F-A90D-1509D954AC08Q40172132-06087E79-0039-4FE0-898B-797740EB888AQ40375636-F5CD4AC7-2A4D-4137-8EF1-EC5D88AFB815Q42969880-BD79CC25-15AB-482E-9F1F-247BF8DA2063Q45887190-29CA228C-34D6-4D53-BA62-A6BF0924B594
P2860
The Ability of Variant Peptides to Reverse the Nonresponsiveness of T Lymphocytes to the Wild-Type Sequence p53264-272 Epitope
description
im Februar 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 2002
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2002
@uk
name
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@en
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@nl
type
label
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@en
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@nl
prefLabel
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@en
The Ability of Variant Peptide ...... pe Sequence p53264-272 Epitope
@nl
P2093
P1476
The ability of variant peptide ...... sequence p53(264-272) epitope
@en
P2093
Albert B DeLeo
Douglas J Loftus
Ettore Appella
Kazuaki Chikamatsu
Koji Nakano
Theresa L Whiteside
Thomas K Hoffmann
P304
P356
10.4049/JIMMUNOL.168.3.1338
P407
P577
2002-02-01T00:00:00Z